Bristol Myers Squibb II-ON RFP: Immuno-Oncology and Cell Therapy

Deadline:
Friday, February 5, 2021 - 5:00pm
Bristol Myers Squibb seeks proposals on topics designed to address questions developed by its Immuno-Oncology and Cell Therapy (IOCT) Thematic Research Center.
Areas of interest:
- Approaches to normalize the tumor vasculature to improve cell therapy/T cell engagers/NK cell engager therapies
- Novel technology which can support cell therapy target identification for solid tumors
- Targeting T cell metabolism pathways to improve T cell fitness for cell therapy in vivo
RFP guidelines:
- Total budgets (direct + indirect) generally should not exceed USD $250k-350k/ 12 month funding period
- Please utilize II-ON Proposal Template for your submission (see Related Documents)
- Collaborating with multiple institutions encouraged
Timeline for submission:
- Proposals due February 5, 2021 to [email protected]
- BMS Review process February 12 – March 5, 2021
- Communication of decisions week of March 12, 2021